Thrombolex Inc.

THROMBOLEX® innovates mechanically channeled thrombolysis, disrupting and dissolving pulmonary embolism thrombus in a single on-the-table session.

06/30/2026

Do more with less.

It is the standard we hold ourselves to - in the design of the BASHIR® Family of Endovascular Devices, in the clinical programs we invest in, and in the resources we make available to the interventional community.

From single-session, on-the-table (OTT) pharmaco-mechanical lysis (PML) to a portfolio built to address the full spectrum of A&VTE, every element of what Thrombolex offers is grounded in one conviction: that better outcomes, efficient delivery, and clinical confidence should be accessible to every clinician and every patient who needs them.

Thrombolex.com

06/26/2026

Pulmonary embolism and venous thrombus require targeted, reliable intervention, and the BASHIR® Family of Endovascular Devices is built to deliver both.

The BASHIR® Endovascular Device and BASHIR® S-B Endovascular Device are FDA cleared for the treatment of PE and venous thrombus, supporting single-session, on-the-table (OTT) pharmaco-mechanical lysis (PML) with integrated mechanical clot fragmentation and targeted thrombolytic delivery. The BASHIR® Plus Endovascular Device offers variable shaft infusion lengths to address venous thrombus with extensive clot burden in a broader range of anatomical presentations.

Thrombolex.com

06/23/2026

For PERT teams, procedural efficiency is not measured in minutes alone. It is measured in the consistency, safety, and clinical confidence delivered for every patient.

In clinical experience with on-the-table (OTT) pharmaco-mechanical lysis (PML) using the BASHIR® Endovascular Device for intermediate-risk PE, the median procedure time was approximately 39 minutes, with no major bleeding events observed in the reported cohort and no requirement for post-procedure infusion. This kind of structured, reproducible outcome is what PERT programs need to build clinical confidence across their institutions.

Thrombolex.com

06/18/2026

In PE care, what happens after the procedure matters as much as what happens during it.

Single-session, on-the-table (OTT) pharmaco-mechanical lysis (PML) using the BASHIR® Endovascular Device is designed to support targeted clot fragmentation and thrombolytic delivery in a structured, efficient intervention, without the need for post-procedure infusion. Clinical experience has demonstrated no major bleeding events in the reported cohort, supporting a pathway that reduces intensive care utilization and total length of hospital stay.

For institutions managing acute PE patients, that kind of post-procedure efficiency is not incidental. It is part of what makes a clinically proven solution worth choosing.

Thrombolex.com

06/15/2026

A strong PERT program depends on having reliable, consistent tools that fit the way your team works.

The BASHIR® Endovascular Device is a standalone technology that requires no capital equipment and integrates into existing lab workflows across a broad range of healthcare facilities. Designed to support single-session, on-the-table (OTT) pharmaco-mechanical lysis (PML), it gives PERT teams a targeted, clinically proven solution that delivers procedural consistency and clinical confidence, without adding complexity to an already demanding care environment.

Thrombolex.com

06/12/2026

The BASHIR® Endovascular Device's expandable infusion basket is engineered for mechanical fragmentation along with uniform delivery of thrombolytics to the segmental branches of the pulmonary arteries, creating focused pharmacologic exposure precisely where clot burden is greatest. This integrated approach supports a controlled, structured intervention that maintains procedural consistency from the first step to the last.

It is not just about where the therapy goes. It is about how reliably it gets there.

Thrombolex.com

06/09/2026

Not all venous thrombus presents in the same way, and not all devices are built to address that variability.

The BASHIR® Plus Endovascular Device is designed for the treatment of venous thrombus with extensive clot burden, offering variable shaft infusion lengths - available in +10, +20, +30, and +40 configurations - to support mechanical fragmentation along with targeted uniform thrombolytic delivery across a range of anatomical presentations. The expandable infusion basket enables precise pharmaco-mechanical lysis without the need for capital equipment, making it straightforward to integrate into existing lab workflows.

Thrombolex.com

06/04/2026

The evidence for single-session PML continues to grow.

Interim data from the first 50 patients in the RAPID-PE Study - a prospective, multicenter U.S. study evaluating on-the-table (OTT) pharmaco-mechanical lysis (PML) - was presented at TCT 2025. The analysis demonstrated that on-the-table PML using the BASHIR® Endovascular Device can be performed efficiently and without post-procedure infusion, offering the interventional community meaningful insight into what structured, targeted PE intervention looks like in practice.

As the study continues to enroll, the RAPID-PE Study reinforces the clinical case for single-session care in acute PE treatment.

Learn more at Thrombolex.com.

06/02/2026

The results of the RESCUE-II Study have been published in JACC: Advances, and the data speaks for itself.

This peer-reviewed publication validates the role of the BASHIR® Endovascular Device as a clinically proven solution in the treatment of A&VTE, demonstrating significant reductions in RV/LV ratio and PA obstruction with no major bleeding events and no requirement for post-procedure infusion. All achieved in a single, on-the-table (OTT) pharmaco-mechanical lysis (PML) session.

In PE care, clinical confidence is earned through evidence. The RESCUE-II Study delivers exactly that.

Read the full publication in JACC: Advances at Thrombolex.com.

05/31/2026

Clinical confidence is built on evidence, and the RESCUE-II Study delivers.

In the RESCUE-II Study, patients treated with the BASHIR® Endovascular Device for acute pulmonary embolism demonstrated significant reductions in RV/LV ratio and PA obstruction, with no major bleeding events and no requirement for post-procedure infusion - all in a single session.

Learn more here: https://www.jacc.org/doi/10.1016/j.jacadv.2025.101789

Thrombolex.com

Address

75 Britain Drive
New Britain, PA
18901

Telephone

+18447926300

Website

http://www.thrombolex.com/

Alerts

Be the first to know and let us send you an email when Thrombolex Inc. posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to Thrombolex Inc.:

Want your business to be the top-listed Health & Beauty Business in New Britain?